author-photo

Monika Jun

6

Papers

26

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ database.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)